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Summary
In recent years there has been increasing awareness of
problems that have undermined trust in medical research.
This review outlines some of the most important issues
including research culture, reporting biases, and statistical
and methodological issues. It examines measures that have
been instituted to address these problems and explores the
success and limitations of these measures. The paper con-
cludes by proposing three achievable actions which could
be implemented to deliver significantly improved transpar-
ency and mitigation of bias. These measures are as follows:
(1) mandatory registration of interests by those involved in
research; (2) that journals support the ‘registered reports’
publication format; and (3) that comprehensive study docu-
mentation for all publicly funded research be made available
on a World Health Organization research repository. We
suggest that achieving such measures requires a broad-based
campaign which mobilises public opinion. We invite readers to
feedback on the proposed actions and to join us in calling for
their implementation.
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Introduction
Significant problems in medical research undermine
efficient scientific discovery and efforts to achieve
improved outcomes for patients. Across scientific dis-
ciplines, a diverse range of issues has resulted in a
situation where published research findings fre-
quently cannot be replicated (‘the reproducibility
crisis’). Meanwhile, avoidable methodological fail-
ings and biases lead to ‘research waste’, which is
estimated to account for 85% of all medical research
funding.1
Many of these problems are rooted in incentives
for individual medical researchers which are poorly
aligned with the wider interests of science. Despite
longstanding calls for ‘less research, better research,
and research done for the right reasons’, concerns
remain that quantity is valued over quality.2 Cultural
problems in medical research are important in them-
selves but also impede progress in tackling biases in
how research is reported and objectively presented.
This review introduces some of the most pervasive
problems in medical research along with an overview
of the current efforts to address these issues. We begin
by describing some of the most significant problems
related to research culture, reporting biases, and stat-
istical and methodological issues. We then outline
some important measures that have been instituted
to address these problems. We conclude with a pro-
posed strategy to help restore confidence in the repro-
ducibility of medical research.
Methods
This paper was informed by literature identified using
a search strategy with the following terms: open sci-
ence, open research, research quality, medic*, health*.
Searches were conducted on CINAHL, EMBASE,
MEDLINE and PsycINFO (Supplement 1).
What are the problems in medical research?
Research culture
Academic rewards system. Academics’ professional
standing depends on demonstrating productivity
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through publication,3 with disproportionate rewards
offered to those who attain publication in ‘luxury
journals’ with high impact factors.4 Journal impact
factors do little to capture the quality or value of
individual research articles and can be manipulated.5
The extraordinary proliferation of research appears
to reflect the pressure for academics to publish
research rather than the development of genuine dis-
covery which could lead to improved outcomes for
patients.6
Conflicts of interests. Financial conflicts of interest have
been shown to affect physician-prescribing habits,
study conclusions and guideline recommenda-
tions.7–10 Potential competing interests have trad-
itionally been regarded as monetary, but may also
include professional, political or personal consider-
ations.11 High-profile scandals have demonstrated
undisclosed conflicts of interest undermine trust in
the objectivity of research.12–14 While non-disclosure
of competing interests does not necessarily affect
assessments of study quality, authors’ interests can
have a bearing on findings.15
Interest disclosures for published research are fre-
quently incomplete.16,17 Conflict of interest recording
and policies in institutions that host research are also
poor, and in several cases journal editors, as well as
researchers, have potential conflicts of interest.18,19
Voluntary declarations from the pharmaceutical
industry have been criticised as inadequate, due to
the ability of individuals to opt out.20 Meanwhile,
other voluntary registers have limited coverage since
they require eligible individuals to ‘opt in’. For exam-
ple, a voluntary register of interests for doctors in the
UK contains details of only 0.002% of all those regis-
tered with the General Medical Council.21,22 In sev-
eral countries, ‘sunshine acts’ require disclosure of
physicians financial interests, and calls have grown
for similar requirements to be introduced to the
United Kingdom.23,24
Reporting biases
‘Reporting bias’ encompasses several sub-biases
caused by selective disclosure or withholding of infor-
mation, either intentionally or unintentionally,
related to study design, methods and/or findings.25
While several types of reporting biases have been
described, we will focus on two of the most widely
studied: publication bias and spin.
Publication bias refers to the propensity of certain
types of research to become published, while other
types remain unpublished. This results in a distortion
of the published record which disproportionately fea-
tures findings that are deemed to be novel, striking or
that provide evidence in favour of a proposed inter-
vention.26 While publication bias is commonly under-
stood to be driven by the perception that journals are
unlikely to accept so-called ‘negative’ or ‘uninterest-
ing’ results, researchers also perpetuate this bias by
failing to submit such research. Publication bias has
also been demonstrated to affect regulatory decisions
and ultimately clinical practice.26 The problem
appears to be culturally entrenched and, in some
cases, conflicts of interest are implicated.7,27 Some
journals have instituted initiatives to encourage pub-
lication of ‘negative’ findings to help remedy publica-
tion bias.28,29
Spin refers to the practice of distorting or misrep-
resenting results to appear more ‘positive’, news-
worthy or interesting.30 While ‘spin’ falls short of
outright falsification or fraud, experiments show
that readers of studies with spin draw more favour-
able interpretations of interventions than when
results are presented more objectively.31 Of particular
concern is that spin in journal abstracts influences
press releases, and studies that obtain press coverage
receive greater numbers of citations.32,33 Spin mani-
fests in a variety of ways including failure to mention
study limitations, selective ordering and highlighting
of outcomes, and drawing exaggerated inferences
from study results.34 Spin appears to be increasingly
common while peer review has proved insufficient to
counter it.35,36 Reviewers who identify spin usually
do not succeed in having it removed from manu-
scripts and some reviewers actually suggest the add-
ition of spin.37
Statistical and methodological issues
There is substantial debate throughout science about
the role of p values in determining statistical signifi-
cance.38 Reporting of p values has become much
more common in recent decades, with 96% of
papers containing p values of 0.05 or less.39 The ubi-
quity of published p values of <0.05 can be explained
by the strong incentives for researchers to publish
significant results.40 p values are also often misinter-
preted and it has been estimated that most claims
based on p values are false.38,41 Some scientists sug-
gest that the threshold of significance for p values
should be reduced or abandoned altogether, that
greater emphasis be placed on effect sizes and confi-
dence intervals, or that Bayesian statistics should be
used to provide greater discriminatory utility when
appropriate.42,43
The availability of modern statistical software
means that, in the absence of an accessible protocol,
it is relatively easy to generate statistically significant
results through repeated analyses, a practice that has
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been dubbed p-hacking.44 P-hacking in turn facili-
tates so called HARKing (Hypothesising After the
Result is Known), whereby researchers can retro-
spectively generate a matching hypothesis to a signifi-
cant p value.45 Researchers may also selectively
report statistically significant results or exploit ‘undis-
closed flexibility’ in how analyses are conducted,
allowing researchers to provide evidence for virtually
any hypothesis.46
Existing measures addressing problems in
medical research
Several measures have been introduced to improve
the reproducibility and transparency of medical
research. Although no individual measure would be
a cure-all, many successes have been documented.
These highlighted achievements demonstrate that
coordinated action to improve the research landscape
is possible and necessary.
A number of important measures are considered in
this article with some additional initiatives outlined in
Table 1 and Table S1 in Supplement 2. It is beyond
the scope of this review to survey all relevant actions
that have been undertaken to address problems in
medical research.
Research culture
Training in medical research, as in clinical medicine,
is based largely around an apprenticeship model.
Much attention has therefore been given to providing
positive mentorship that promotes integrity.47 Several
initiatives such as the UK Reproducibility Network
have been established to promote values and prac-
tices in research conducive to the principles of open
science within academic institutions.48
Several other measures have been proposed in
order to align academic promotion criteria with
responsible research practices. Suggestions include
appraising research quality and reproducibility, and
placing limits on the volume of publications that can
be periodically submitted for institutional apprai-
sal.49–52 The San Francisco Declaration on
Research Assessment (DORA) and the Hong Kong
Principles have been formulated improve the assess-
ment of researchers while the Transparency and
Openness Promotion guidelines (TOP) includes sev-
eral standards by which to assess research and
journals.53–55
Reporting biases
Clinical trial registration. Many of the problems outlined
above, such as publication bias, spin, HARKing and
p-hacking occur after research has been conducted.
‘Pre-registering’ studies prior to collecting data estab-
lish a record of research scheduled to take place
including the hypotheses, methods, analyses and out-
comes. Researchers can then be held accountable to
the methods and outcomes they prespecified and
expected to justify any deviations.
Registration of clinical trials is promoted by the
World Health Organization through a number of
approved primary registries and has increasingly
become an expectation of funders and publishers.56,57
The requirement by the International Committee of
Medical Journal Editors is that all trials should be
registered before being considered for publication
and the passage of the FDA Amendments Act 2007
mandating registration in the USA were major mile-
stones in achieving widespread trial registration.58,59
Mandatory registration requirements have in turn
facilitated mandatory reporting requirements, with
the expectation that full findings of all trials are dis-
seminated in some form, be it through journal publi-
cation or alternate routes provided by regulatory
bodies or trial registries.60 As well as from clinical
trials, systematic reviews are also routinely registered
prior to study commencement.61
Registration should be understood as one tool to
help ensure researchers share their results and to dis-
courage unjustified deviations from research plans.
However, registration alone is not a panacea. For
example, undeclared ‘outcome switching’ between
registration and publication is common among regis-
tered trials.62 Journals could routinely ensure that
reported outcomes match pre-specified registered out-
comes. Despite these caveats, the value of registration
should not be understated, since without it such devi-
ations would not be detectable at all.63,64
Registration of non-trial research. Although registration
is now an expectation for clinical trials and systematic
reviews, it remains voluntary and is employed rela-
tively infrequently for other research types. For
example, observational studies would benefit from
registration and pre-specification of hypotheses and
methods. Free public platforms, such as the Open
Science Framework, are a highly accessible means
for all researchers to publish time-stamped protocols
and analysis plans. We believe that registration or
publication of a priori protocols should become an
expectation, and justified when not present. Broad
adoption of study registration and protocol publica-
tion could dissuade authors from presenting results
from exploratory work as hypothesis-based research,
combat p-hacking and HARKing, and create a per-
manent record of planned research that can mitigate
publication and other reporting biases. ‘Registered
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Table 1. Initiatives and organisations working to reduce waste and improve the openness and quality of research.
Category Initiative/Organisation Description URL




Open Science Badges Badges appended to publications
to acknowledge and incentiv-
ise open science practices.
https://cos.io/our-services/
open-science-badges/
REWARD Alliance Originated in 2014 Lancet series
on waste in research.
Promotes efforts to increase
the value of research and
reduce waste in research.
http://rewardalliance.net/
San Francisco Declaration on
Research Assessment
(DORA)
Initiative which calls for





Initiative which promotes the
practices of open science.
https://bristol.ac.uk/psychol
ogy/research/ukrn/
Reporting biases AllTrials Campaign to ensure all clinical
trials are registered and
published. Highlights problem
of publication bias, e.g.
through ‘unreported clinical









accurate reporting and wider




TranspariMED Campaigning organisation which
advocates for registration and









Online platform that facilitates
open sharing and preregistra-
tion of research.
https://osf.io/
Oxford – Berlin summer
school on open research
Training for researchers











to promote evidence based
clinical research, particularly
the need to use systematic
reviews when planning new
studies and when placing new
results in context.
https://evbres.eu
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Reports’ are a related initiative which is discussed
below.
Publication checklists. One initiative employed to
improve transparency and quality of reporting has
been the widespread requirement by journals for
authors to submit checklists along with manuscripts,
indicating whether reporting standards have been
met. Checklists now exist for all major study designs
of which the Consolidating Standards of Reporting
Trials (CONSORT) is perhaps the best known and
endorsed by hundreds of journals.65 CONSORT has
been associated with some improvement in complete-
ness of reporting, but instances of poor CONSORT
compliance remain.63,66 Even when discrepancies are
clearly identified by journal readers, authors and
journal editors infrequently make corrections.64
While the existing self-regulation of checklist compli-
ance has yielded imperfect results, journal editors, or
perhaps specially trained editorial assistants, could
vet publications to ensure accurate reporting before
publication.67
Statistical and methodological issues
Education. The importance of high-quality training in
statistics and open science methods are increasingly
recognised.68,69 Several educational opportunities
have been established, some of which are identified
in Table 1 and Supplement 2. Although such training
is welcome, only a small proportion of medical
researchers will benefit from such initiatives with
access limited in low- and middle-income countries.70
Therefore, it is vital that capacity to deliver such
training is developed and maintained within aca-
demic institutions.
Data sharing. For research to be fully appraised and
potentially reproduced, additional information
beyond a study publication is required. Registrations
can provide some additional detail, but in many
cases, other documentation such as study protocols,
analysis plans and individual patient data are neces-
sary to understand and assess or reproduce the study.
Making such data available would also allow other
researchers to use the same data to answer different
research questions.71 Unfortunately, research data
are often not made available, even in summary forms
or through securemechanisms thatwouldminimise the
risks to breaches of patient privacy and
confidentiality.72–75
The International Committee of Medical Journal
Editors has instituted requirements for data sharing
for published clinical trials. While such policies are
welcome, research suggests that even with these
requirements data are available in only about half
of publications.72 Persuasive appeals have been
made to institute greater data sharing for all study
types, including the proposition that research papers
become one of a series of ‘threaded documents’ with
underlying data made available as a matter of
course.71,76 Several data-sharing platforms are avail-
able to researchers.77,78
How to improve medical research?
Significant gains in transparency have been achieved
in clinical trial registration through the combined
efforts of researchers, journals, funders, campaigners
and legislators. Meanwhile continued attention has
been brought to the ‘reproducibility crisis’ through
the Open Science movement, which has connected
international collaborators who share a determina-
tion to improve scientific practice through meta-
scientific study. While it remains vital that emphasis
is placed on improving statistical and ethical educa-
tion for researchers and on addressing cultural issues
within research, there is a need for immediate and
definitive action to improve the quality of medical
research.
We propose a strategy that includes three measures to
achieve further improvements in the transparency of
medical research. These measures are:
1. mandatory registration of interests for all people
and institutions who conduct and publish health
research;
2. all journals and funders support uptake of regis-
tered reports; and
3. publicly funded research is pre-registered and pub-
lished on a World Health Organization-affiliated
research registry.
Box 1 outlines how this strategy was developed, and
Table 2 summarises some of the ways this could
improve research.
Mandatory declaration of interests. To establish trust in
the objectivity of research, researchers must become
more open about conflicts or declarations of interests.
The brief voluntary statements in publications are not
sufficient to meet this expectation. A fully accessible
database of interests should be established, with firm
expectations of accurate, up-to-date and comprehen-
sive disclosure from all researchers, doctors, institu-
tions and patient advocacy groups. Such disclosures
should feature both monetary payments, benefits
such as travel, hospitality and conference fees, and
non-monetary interests, such as memberships of com-
mittees. Researchers’ declaration of interests should
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be required by all academic institutions, funders and
journals. The Open Research and Contributor ID
(ORCID) system already catalogues the identities of
over 7 million researchers. Hence, ORCID could be
an option to index researchers’ interests.79
Registered reports. Registered reports are a publication
format that permits authors to submit their proposed
methods and analysis plan to a journal prior to con-
ducting the research. If the journal accepts the pro-
posal, it commits to publication as long as
the research is satisfactorily conducted, regardless of
the findings.80 This model can help limit the impacts
of publication bias and other reporting biases.
Registered reports also curtail both the ability of
authors to undertake (or peer reviewers to request)
HARKing or p-hacking, and reduce the incentive to
do so. Underpowered research or questionable meth-
odological or statistical decisions can be identified
and addressed through peer-review prior to study
conduct. Since journals commit to publication upon
review of study plans, rather than finished papers,
registered reports may reduce the incentive for
authors to ‘spin’ and for reviewers to request such
embellishments.
Authors are not restricted from undertaking addi-
tional exploratory analyses, but registered reports
help clarify that such analyses are exploratory and
not based on prior hypotheses. Null findings are
more likely to be published through registered reports
than traditional formats and registered reports are
cited just as often as conventional papers.81,82
At the time of writing, registered reports were
accepted by 225 journals, which included only 68
(1.3%) of the 5250 journals indexed in MEDLINE
(Supplement 3).80 A precursor to the registered report
format was introduced by the Lancet over 20 years
ago, but was discontinued with the warning that
some studies deviated substantially from pre-specified
outcomes and analyses.83 This experience suggests
that consistent evaluation of registered reports and
support for authors to use the format is required.
Their successful adoption in other scientific disci-
plines suggests medical journals could adopt this
format in much greater numbers than they currently
do. Pressure from funders, authors, readers and edi-
torial board members could help support journals to
make this transition.
Comprehensive research registration and publication. To
facilitate reproducibility of research findings and to
assess the plausibility of scientific claims, it is essential
that documentation, including protocols and analysis
plans, are made available to peers. Making all study
findings available is the only way to address publica-
tion bias. It is also a matter of fairness that research
which is paid for by public or charitable funding, and
upon which important healthcare decisions may be
made, is made available for anyone to view.
For all publicly funded research, not just trials,
comprehensive documentation including protocols,
statistical analysis plans, statistical analysis code,
raw or appropriately de-identified summary data,
and results should be available on a World Health
Organization-affiliated open access registry. In
theory, the Food and Drug Administration already
requires that protocols and statistical analysis plans
for clinical trials are publicly shared.59 Obtaining
widespread compliance with this principle for most
types of study would represent a significant, but
achievable, advance in transparency and fairness.
Funders should require that study documentation is
made openly available, while governmental and
national research institutions could support the
development, or nomination of, an appropriate
open platform where anyone can find comprehensive
information about publicly funded research.
Important principles such as the range of docu-
mentation that should be shared and to what level
of detail would need to be established. However, we
believe that establishing the expectation that suffi-
cient information should be available for research
to be adequately appraised could be an important
milestone in achieving greater transparency and
reproducibility.
Box 1. Development of the authors’ strategy to achieve
further improvements in medical research.
The concept of a campaign, with specific objectives to
improve health research arose from a presentation made
to the EBMLive conference in Oxford in July 2019. The
conference organisers facilitated a further session to
discuss the concept further, chaired by Georgia
Richards. An online survey was distributed among
attendees of the conference session. Survey results were
used to inform selection of three demands.
Drafts of a statement were prepared by Stephen Bradley,
Peter Gill and Georgia Richards and distributed among
conference attendees, who then provided feedback and
became signatories. A draft statement was made avail-
able (https://osf.io/k3w7m/) in October 2019 and pub-
licised via twitter (@TA_Declaration).
The feedback received informed the second major revision
of the declaration, which, following consultation with
signatories, was made available in January 2020. Signing
the statement and/or providing feedback is possible by
completing this form: https://docs.google.com/forms/d/
1wHWcw77fFtvvvY2tJpNrzflt3HE0tF8xvFOL3U55RV4/
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Study accepted for publication
based on methods, not results
Study results and documents made
available, regardless of publication
status
‘Spin’ Practice of presenting results








Reduced incentive to ‘spin’ to obtain
publication
Study documentation available to
allow greater scrutiny of
researchers’ claims
Information on possible conflicts of
interest allows peers to judge if
researchers have vested interest
in applying spin to study
Scientific fraud Deliberate falsification of evi-
dence, for example fabri-
cation of results.
Research Registry Availability of full study documenta-
tion allows peers to scrutinise
results. Researcher compelled to
demonstrate ‘not just the answer





researchers of fulfilment of
checklist statements.
Research Registry Peers can scrutinise methods from
available study documentation
HARKing Researchers generate
hypotheses to fit results
and present these as if
formulated prior to
obtaining results.
Registered Reports Hypotheses and aims are agreed
prior to undertaking research.
Any further post hoc analyses are
declared as such
P-Hacking Researchers manipulate
results until findings gen-




Analyses agreed prior to generation
of results
Analysis plans and code available to
peers for scrutiny










Outcomes of interest agreed prior
to undertaking research
Protocols and analysis plans made
available to peers for scrutiny
Conflicting interests which could












Methods are agreed prior to publi-
cation. Incentive to generate
results which favour publication
removed
Protocol and analysis plan made
available to peers for scrutiny
Undisclosed conflicts
of interest
Researchers may have, or
could be perceived to






Researchers compelled to made
comprehensive statement of
their pecuniary interests, gifts and
hospitality received and non-
pecuniary interests
(continued)
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Implementation
Implementing the proposed measures would likely
impose financial and opportunity costs. Registered
reports could create additional workload for journals
and peer reviewers, and shift substantial work to ear-
lier in the lifecycle of a project which may have fund-
ing and resource implications for research teams.
Additionally, establishing a register of interests and
a dedicated research repository would require invest-
ment from research funders and regulators, as well as
the participation of researchers and industry. We
believe the measures are proportionate, particularly
in the context of the profits generated by the publish-
ing industry from research84 and the large sum of
public resources invested to produce those findings.1
The implementation of registers elsewhere, even in
highly decentralised healthcare settings like the
USA, is a proof of concept for the viability on
other settings. While researchers might be reluctant
to accept additional administrative burdens, deposit-
ing interests and study data in central and accessible
locations could help reduce duplicative reporting
requirements.
Important stakeholders such as research funders,
regulators and journal editors are likely to have the
most influence in achieving change. Yet the experi-
ence of inconsistent compliance with existing require-
ments85–87 suggests that cultural change is also vital.
Campaigns that raise awareness and expectations of
transparency from the public88–90 and legislators91
along with social pressure from peers92 are likely
to help with embedding improvements in research
culture.
Conclusions
Significant progress is required to satisfy reasonable
expectations that medical research is trustworthy,
reproducible and represents value for money. The
proposed strategy comprising mandatory registration
of potentially competing interests, registered reports
and requiring all publicly funded research is regis-
tered can be readily conveyed to policy makers and
rapidly implemented. These ideas are not novel and
we do not claim that they would solve all problems in
medical research. But, while such profound problems
persist in medical research, we believe that it is time
to implement simple measures to achieve greater
transparency, reduce reporting biases and deter
poor methodological practices.
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